Noxafil (posaconazole) / Merck (MSD), Ligand - LARVOL DELTA

The effect of belumosudil on the therapeutic monitoring of tacrolimus and sirolimus in allogeneic hematopoietic transplantation (ASH 2025) - "Azoles were used concomitantly in 51.5% of patients (35/68), with 65.7% (23/35) on posaconazole, 31.4% (11/35) on isavuconazole, and 2.9% (1/35) on voriconazole. Four patients started an azole after starting belumosudil (2 on posaconazole, 1 on fluconazole, and 1 on isavuconazole)... Our study confirms the drug interaction between TAC/SIRO, with the increase in TAC/SIRO levels more pronounced with the second level after starting belumosudil. However, severe toxicities were rarely seen. Based on our data, we recommend close TDM of TAC and SIRO, but no dose adjustment is warranted when belumosudil is added."

Acute Kidney Injury • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Movement Disorders • Nephrology • Transplantation • CYP3A4

Dose modifications of mezigdomide when coadministered with CYP3A4 inhibitors for patients with relapsed/refractory multiple myeloma (ASH 2025) - P1/2 | "Introduction: Mezigdomide (MEZI), an oral CELMoD™ agent with potent antimyeloma and immunostimulatory effects, has demonstrated encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) as monotherapy and in combination with dexamethasone/standard treatments (CC-92480-MM-001 [NCT03374085]; CC-92480-MM-002 [NCT03989414])...A phase 1 clinical drug–drug interaction (DDI) study in healthy participants evaluated MEZI as a substrate of cytochrome P450 3A4 (CYP3A4), using rifampin (strong inducer) and itraconazole (strong inhibitor)...Specifically, MEZI CL was reduced 0.15-, 0.11- and 0.38-fold when administered with posaconazole, voriconazole, and fluconazole, respectively... MEZI is a sensitive CYP3A4 substrate. Modeling and simulation provide a robust framework to guide dose adjustments and manage potential DDI risks while preserving efficacy. For pts requiring concomitant use of strong or moderate CYP3A4is, MEZI can be continued safely with dose..."

Clinical • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia

IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent (ASH 2025) - "All pts received at least one cycle of HMA therapy, consisting of either azacitidine (75 mg/m²) or decitabine (20 mg/m²), combined with venetoclax, typically dosed at 100mg daily with posaconazole prophylaxis. The primary limitations of this study include its retrospective design, sample size, and variability in the timing of response assessment. Despite these limitations, this study supports further development of treatment-specific, genetics-enhanced, and response-based prognostic tools in AML."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • FLT3 • IDH1 • IDH2 • NPM1 • TP53

Venetoclax pharmacokinetics with triazole prophylaxis in patients with Acute Myeloid Leukemia in India: Pilot study (ASH 2025) - "Limitations include the small sample size and incomplete recording of venetoclax dose and meal status (precluding dose-normalized analysis). Even so, these early data offer actionable guidance on venetoclax use in India: posaconazole-enabled dose reduction may safely achieve target exposures, while voriconazole may require additional dose adjustments."

Clinical • PK/PD data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia

Comparative outcomes of posaconazole vs. voriconazole/isavuconazole for antifungal prophylaxis in neutropenic adults with Acute Myeloid Leukemia: A propensity-matched retrospective cohort study (ASH 2025) - "In this large, matched cohort of neutropenic AML patients, posaconazole prophylaxis was associated withimproved survival and reduced incidence of shock compared to voriconazole/isavuconazole, albeit at thecost of slightly increased hospitalization. These findings support the preferential use of posaconazole inselect high-risk AML populations, while highlighting the need for individualized risk–benefit assessmentin antifungal prophylaxis strategies."

Retrospective data • Acute Myelogenous Leukemia • Acute Respiratory Distress Syndrome • Candidiasis • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Ophthalmology • Respiratory Diseases

Secondary-type acute myeloid leukemia is associated with a higher risk of invasive fungal infection during intensive induction therapy. a correlative study on the ALFA 0702 trial. (ASH 2025) - P2 | "447 (71%) pts receivedanti-fungal prophylaxis during the first intensive course (posaconazole n=360, other n=87)...Genetically-defined secondary-type AML patients might be more susceptible to IFI duringintensive AML induction therapy regardless of baseline ANC and duration of neutropenia. These findingsmay guide personalized IFI prevention policies in this population."

Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • ASXL1 • BCOR • BCORL1 • RUNX1 • SETBP1 • SF3B1 • SRSF2 • STAG2 • U2AF1 • ZRSR2

Preliminary Results of A phase 1 study of the safety and tolerability of the combination of revumenib (REV) with gilteritinib (GILT) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (ASH 2025) - P1 | "One pt had successful dose re-escalation after discontinuation of posaconazole without recurrent QTc prolongation. This is the first clinical study evaluating the combination of menin and FLT3 inhibitors fortreatment of R/R AML. We have demonstrated that REV can be safely combined with GILT withencouraging preliminary efficacy. QTc prolongation is a DLT when combined with a strong CYP3A4inhibitor."

Clinical • P1 data • Acute Myelogenous Leukemia • Febrile Neutropenia • Hypotension • Infectious Disease • Neutropenia • Pulmonary Disease • FLT3 • KMT2A • MEIS1 • NUP98

Efficacy and safety of clia plus venetoclax as salvage therapy for relapsed or refractory Acute Myeloid Leukemia (ASH 2025) - "Induction consisted of cladribine 5 mg/m² IV days 1–5, idarubicin 10 mg/m² days 1–3, cytarabine 1500mg/m² days 1–5, and venetoclax 400 mg PO daily days 2-8...Venetoclax doses were reduced to 200 mg withfluconazole and 70 mg with posaconazole prophylaxis... CLIA-ven appears to be an effective and well-tolerated salvage regimen in a heavily pretreated cohortwith relapsed/refractory AML, achieving high rates of remission with a substantial proportion achievingMRD negativity. While only a minority of patients proceeded to allogeneic transplant in this series, theregimen may provide an important option for achieving remission and facilitating transplant candidacy."

Clinical • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • DNMT3A • FLT3 • JAK2 • TP53 • U2AF1 • WT1

CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study (ASH 2025) - P3 | "Introduction Ivosidenib (IVO) is an oral, targeted, small-molecule inhibitor of mIDH1 approved for the treatment of ptswith mIDH1 AML. In the pivotal AGILE study of IVO in combination with azacitidine (AZA) in newlydiagnosed AML (NCT03173248), the most common grade ≥3 adverse events (AEs) were hematologic inboth the IVO+AZA and placebo (PBO)+AZA arms (Montesinos, NEJM 2022)...Forexample, venetoclax requires dose reduction when administered concomitantly with CYP3A4i, yetincreased exposure and myelosuppression still occur (Kawedia, AJH 2025)...Population PK modeling predicted theAUC of IVO at SS to increase moderately (<2-fold) when coadministered with voriconazole, fluconazole,and posaconazole—by 48.7%, 60.8%, and 58.8%, respectively—compared with IVO alone...However, low rates of individual AEs limit the ability to draw firm conclusions.IVO exposure was predicted to increase <2-fold when given in combination with moderate/strongCYP3A4i. As concomitant use of..."

Clinical • P3 data • Acute Myelogenous Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Thrombocytopenia • CYP3A4 • IDH1 • TINCR

Treatment initiation pattern, ramp-up measures and management of AML patients treated in real life in Italy with venetoclax+azacitidine - first interim analysis of the prospective vero study (ASH 2025) - P | "Prophylactic measures were adopted in 62 (82.7%) patients asfollows, consisting of hypouricemic agents treatments in 42 patients, blood chemistry monitoring in 42patients, cytoreduction in 26 patients, (24 treated with hydroxyurea and 2 with cytarabine) andintravenous hydration in 36 patients.The ramp-up was performed according to different schedules and as per label only in 11 patients: 100-200-400mg in 11 patients; 100-200mg in 20 patients; 50-100-200mg in 2 patients; 10-20-50mg in 10patients. Other treatment initiation schedules were observed in 8 patients.During cycle 1,Ven was administered to 74 patients, with a mediantreatment duration of 28 days (Q1-Q3:21-28) per 28-day cycle and a median dose of 133.3 mg/day (100-225). In cycle 2, 53 pts received thetreatment for a median of 28 days (Q1-Q3: 22-28) with a median dose of 100 mg/day (100-233).Finally, incycle 3, 47 patients were treated for a median of 28 days (Q1-Q3: 21-28) with a median dose of 200mg/day..."

Clinical • Acute Myelogenous Leukemia • Chronic Kidney Disease • Nephrology • Renal Disease • IDH1 • IDH2 • NPM1 • TP53

Improved outcomes with low-dose hypomethylating agent plus venetoclax as post-transplant maintenance in patients undergoing reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for myeloid malignancies (ASH 2025) - "The use of low dosehypomethylating agents (HMAs) such as azacitidine (AZA) or decitabine (DEC) in combination withvenetoclax (VEN) has been shown to be a feasible post-HSCT maintenance strategy in myeloidmalignancies...Patients treated with post-HSCT HMA+VEN maintenance were matched in a 1:1 ratio to patients not receiving maintenancefollowing a hierarchal algorithm based on age at transplant, disease type (AML vs. MDS), risk stratification(ELN for AML and IPSS-M for MDS), disease status at transplant, donor type, Fludarabine/Melphalan(Flu/Mel) conditioning and year of diagnosis...The dose of VEN was reduced to 20mg when administered with voriconazole or posaconazoleor 100mg when administered with fluconazole or isavuconazium...More patients in the maintenancegroup received post-transplant cyclophosphamide-based graft versus host disease (GVHD) prophylaxis,compared to the no maintenance group (49% vs. 31%, p=0.03).Maintenance was initiated after a median of 58d (range..."

Clinical • Post-transplantation • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Neutropenia • Thrombocytopenia • Transplantation

A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trial (ASH 2025) - P2 | "Patients receive VEN 400 mg (50 mg ifconcomitant posaconazole) on days 1-28 in association with azacitidine 75 mg/m2 days on 1-7. This preliminary data shows encouraging results for AZA-VEN in preventing disease relapse,deepening molecular responses and bridging safely and effectively NPM1m AML patients in MF toalloSCT. Updated data from ongoing patients will be presented at meeting in case of Abstract selection.This study has been conducted with the support of AbbVie srl."

IO biomarker • P2 data • Residual disease • Acute Myelogenous Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Thrombocytopenia • Transplantation • ABL1 • FLT3 • NPM1

Clinical and microbiological insights into invasive fusariosis following allogeneic hematopoietic stem cell transplantation: A 15-year single-center analysis (ASH 2025) - "Baseline characteristics betweenpatients with and without IF were compared using appropriate parametric and non-parametric tests.Overall survival (OS), and day 28, 84, and 1-year mortality were estimated using the Kaplan–Meiermethod, and univariate comparisons of clinical factors—including age, sex, performance status,conditioning intensity, prior HSCT, neutrophil recovery, monotherapy vs combination therapy withliposomal amphotericin B (L-AMB) and voriconazole (VRCZ), and steroid use—were conducted using thelog-rank test. Seventeen patients with proven IF and 2,342 without IF were analyzed...All patients received antifungalprophylaxis: micafungin (n = 10), posaconazole (n = 4), or VRCZ (n = 3)... Seventeen patients with proven IF and 2,342 without IF were analyzed. The incidence of IFamong allogeneic HSCT recipients was 7.2 cases per 1,000 transplants. Most cases occurred in patientstransplanted in non-complete remission (94.1% vs."

Clinical • Bone Marrow Transplantation • Cerebral Hemorrhage • CNS Disorders • Hematological Malignancies • Infectious Disease • Neutropenia • Septic Shock • Transplantation

A phase 1/2 study of GB3226, a novel dual inhibitor of ENL-yeats and FLT3, in patients with relapsed/refractory Acute Myeloid Leukemia (ASH 2025) - P1/2 | "Phase 2 of the study aims at assessing the efficacy of GB3226, measured by the rate of completeremission (CR) and CR with partial hematologic recovery (CRh).Additionally, the study will explore pharmacodynamic (PD) markers in peripheral blood and bone marrowto elucidate GB3226's biological effects and identify potential biomarkers predictive of clinical response. This open-label, multicenter, seamless Phase 1/2 study will enrol adult patients (aged ≥18years) with R/R AML, who have failed at least one prior line of therapy (e.g., chemotherapy, venetoclax-based regimens). Phase 1 employs a dose-escalation design across three cohorts to assess the impact of CYP3A4 inhibitorson GB3226 PK and safety and define the maximal tolerated dose (MTD).Cohort A: No CYP3A4 modifiersCohort B: Coadministration with strong CYP3A4 inhibitors (e.g., voriconazole, and posaconazole)Cohort C: coadministration with moderate CYP3A4 inhibitors (e.g., isavuconazole)GB3226 is administered..."

Clinical • P1/2 data • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • CD14 • FLT3 • HEY1 • HOXA9 • ITGAM • MEIS1

The efficacy and safety of venetoclax-based and anthracycline-free induction therapy followed by allogeneic hematopoietic stem cell transplantation in the treatment of transplant-eligible Acute Myeloid Leukemia patients (ASH 2025) - "MethodThe induction therapy included venetoclax plus a standard dose of cytarabine (venetoclax 100 mg plusposaconazole 300 mg per day until remission; cytarabine 100 mg/m2/day x 7), or venetoclax plusazacitidine (venetoclax 100 mg plus posaconazole 300 mg per day until remission; azacitidine 75mg/m2/d x 7). ConclusionThis is the first feasible experience of a venetoclax-based and anthracycline-free regimen followed byallogeneic hematopoietic stem cell transplantation in the treatment of transplant-eligible AML patientswith a significantly higher remission rate, transition to transplant rate, and overall survival as comparedwith traditional 3 + 7 followed by allotransplant. But there was no significant difference in terms of overallsurvival when either induction therapy was followed by allogeneic hematopoietic stem celltransplantation."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Leukemia • Lung Cancer • Lymphoblastic Lymphoma • Lymphoma • Mucositis • Multiple Myeloma • Pneumonia • Respiratory Diseases • Solid Tumor • Stomatitis • Transplantation

Fungal infections following chimeric antigen receptor T-cell (CAR-T) cell therapy: A retrospective case-control study in the south-central US (ASH 2025) - "Twopatients had bloodstream infections (BSI) breaking through micafungin, one with Cryptococcusneoformans, and one with Candida krusei. Another three patients broke through fluconazole, one withCandida glabrata BSI, one with Candida krusei BSI and one with Aspergillus pneumonia. The last twopatients broke through posaconazole, one with invasive aspergillosis and one with Trichodermapneumonia... While uncommon, invasive fungal infections tend to occur early after CAR-T therapy and are associatedwith markedly increased mortality despite antifungal prophylaxis. Patients with B-ALL, particularly thosewith a prior allogeneic HCT, patients with prolonged neutropenia or CMV reactivation after CAR T, seemto be at the highest risk. Larger prospective studies are needed to identify the subset of CAR-T recipientsto target for individualized antifungal prophylactic strategies."

CAR T-Cell Therapy • Retrospective data • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases

Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for acute lymphoblastic leukemia following allogeneic stem cell transplantation (ASH 2025) - P2 | "All donor and stem cell sources were included.Treatment: Up to 12 cycles of VEN 200 mg on Days 1–7 and AZA 32 mg/m² SC on Days 1–5 every 28 days.VEN was reduced for patients on CYP3A inhibitors (e.g., 40 mg with posaconazole). VEN/AZA maintenance post-SCT in high-risk ALL is feasible and well-tolerated, with promisingRFS and OS outcomes. Our findings support further investigation of VEN+AZA maintenance in larger,multi-center studies."

Clinical • Combination therapy • P2 data • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Multiple Myeloma • Neutropenia • Thrombocytopenia • Transplantation

Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation (ASH 2025) - "All donor and stem cell sources were included.Treatment: Up to 12 cycles of VEN 200 mg on Days 1–7 and AZA 32 mg/m² SC on Days 1–5 every 28 days.VEN was reduced for patients on CYP3A inhibitors (e.g., 40 mg with posaconazole). VEN/AZA maintenance post-SCT in high-risk AML appears to be feasible and demonstratesencouraging RFS and OS rates at 1- and 2-years. Despite frequent hematological toxicity, the regimen wasgenerally well tolerated with low rates of NRM. Our findings support further investigation of VEN+AZAmaintenance in this setting to improve alloSCT outcomes, including randomized trials and expansion tointermediate risk AML cohorts."

Clinical • Combination therapy • P2 data • Acute Myelogenous Leukemia • Febrile Neutropenia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Neutropenia • Pneumonia • Respiratory Diseases • Thrombocytopenia • Transplantation

Intrinsic resistance to short-tailed azoles in the basal fungus Mucor lusitanicus: functional analysis of Cyp51 isoforms and amino acid substitutions. (PubMed, Front Microbiol) - "The basal fungus Mucor lusitanicus (Mlu) is a cause of mucormycosis, with limited treatment options due to intrinsic resistance to short-tailed azoles (fluconazole, voriconazole) and echinocandins. Susceptibility to long-tailed azoles (e.g., posaconazole) remained unchanged for both isoforms. These findings demonstrate the functional expression of MluCyp51-F1 and MluCyp51-F5 isoforms in a phylogenetically distant host and confirm that conserved substitutions Y129F and V293A in MluCyp51-F5 confer intrinsic resistance to short-tailed azoles in M. lusitanicus."

Journal • Infectious Disease

Species distribution, antifungal susceptibility, and clinical profiles of patients with osteoarticular fungal Infections: A retrospective study. (PubMed, New Microbes New Infect) - "Fungal identification was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), followed by broth microdilution antifungal susceptibility testing for amphotericin B (AMB), fluconazole (FLC), voriconazole (VRC), and posaconazole (POS). Antifungal susceptibility testing revealed VRC and POS as potentially effective therapeutic options for OAFIs. These findings underscore the need for early detection of rare fungal pathogens, susceptibility-guided therapy, and continuous resistance surveillance in managing OAFIs in non-immunodeficient patients."

Journal • Retrospective data • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Musculoskeletal Diseases • Rheumatology

Non-Aspergillus molds. (PubMed, JHLT Open) - "In general, lipid preparations of amphotericin B or azole antifungals (voriconazole, posaconazole, isavuconazole) are frequently used for treatment. Investigational therapies such as fosmanogepix or olorofim are promising as future treatment modalities for some of these difficult-to-treat non-Aspergillus molds."

Journal • Review • Cardiovascular • Hematological Disorders • Infectious Disease • Neutropenia • Respiratory Diseases • Thrombosis • Transplantation

Candida glabrata vertebral osteomyelitis following L3-4 transforaminal lumbar fusion: illustrative case. (PubMed, J Neurosurg Case Lessons) - "This case highlights the diagnostic and therapeutic challenges of postoperative C. glabrata vertebral osteomyelitis. Early suspicion, culture confirmation, and organism-specific antifungal therapy, alongside timely surgical management, are critical to achieving infection control and preserving spinal stability in immunosuppressed patients. https://thejns.org/doi/10.3171/CASE25555."

Journal • Infectious Disease • Inflammation • Orthopedics

Evidence Based Approach of Antifungal Prophylaxis (AFP) in Hematological Malignancies (DGHO 2025) - "Ten trials with HMA monotherapy (n=1,185), 10 with HMA/venetoclax (n=956) and 4 with FLT3-inhibitors (n=273) were analyzed...No prospective RT for AFP with isavuconazole, rezafungin or olorofim are available.In pts receiving HMA therapy, IFI ranged between 1.6 and 10.3% while AFP was usually not given...In pts treated with midostaurin, two studies (n= 218 pts) reported 29 IFI (13.3%). A total of 20,753 AFP pts episodes (eps) were included since 1984 from 95 studies during CTx and 17,482 pts received AFP within a clinical trial for AFP from 1992 to 2022. Out of these, 7,586 received fluconazole (FLU), 4,080 were on trials with posaconazole (POS) or voriconazole (VOR), 1,717 received itraconazole (ITRA), 1,895 echinocandins and 1,594 amphotericin B (AmB)(AmB deoxycholate, liposomal AmB or inhalative AmB), respectively. In pts receiving novel targeted therapies (e.g."

Hematological Malignancies • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Neutropenia • Oncology

The Use of Antifungal Prophylaxis Is Associated with Worse Outcomes in Patients with Newly Diagnosed AML Treated with Venetoclax/HMA: A Retrospective Analysis of Patients in the Flatiron Health Database (ASH 2024) - "Among patients who received AFP, 172 (41%) received fluconazole, 128 (30%) received voriconazole, 52 (12%) received isavuconazole, and 68 (16%) received posaconazole. This further limited the ability to assess how venetoclax doses were modified. Finally, there may have been selection bias with some patients receiving antifungal prophylaxis because of additional patient or disease-related characteristics that could have impacted outcomes."

Retrospective data • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • ASXL1 • RUNX1 • TP53

40 Years of Preventing Fungal Infections in Hematological Malignancies - Lessons Learned from Clinical Trials with 20,753 Patients (ASH 2024) - "Out of these, 7,586 received fluconazole (FLU), 4,080 were included in trials with posaconazole (POS) or voriconazole (VOR), 1,717 received itraconazole (ITRA), 1,895 echinocandins and 1,594 amphotericin B (AmB)(AmB deoxycholate, liposomal AmB or inhalational AmB), respectively...No prospective studies for AFP with isavuconazole and new antifungal agents like rezafungin or olorofim are available...In those receiving venetoclax/HMA, AFP practices were heterogeneous and IFI incidence ranged from 5% to 16.1% (overall probable/proven IFI : n=102 (10.6%), possible IFI not reported in all studies). In pts treated with midostaurin, 2 studies (n= 218 pts) reported 29 probable/proven IFI (13.3%). In pts treated with gilteritinib, 2 studies reported 55 pts with an IFI rate of 27.2% (including possible IFI)...Despite numerous trials for prevention of IFI, only posaconazole and fluconazole proved reduction in OM rates. There is a need for prospective clinical trials addressing..."

Clinical • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Neutropenia • Oncology